secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070291
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema Q1 2025: $392.7M cash, net loss $30.4M; palazestrant combo mPFS 13.8 months
--------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities of $392.7M at March 31, 2025; net loss $30.4M.
- Updated mPFS from Phase 1b/2: 13.8 months (all patients) and 13.1 months (prior CDK4/6i) for palazestrant+ribociclib.
- Phase 3 OPERA-01 top-line data expected in 2026; OPERA-02 in frontline breast cancer to start in 2025.
- GAAP R&D expenses $30.6M in Q1 2025, up from $29.9M; non-GAAP R&D $27.3M excluding stock comp.
- OP-3136 Phase 1 trial enrollment ongoing; preclinical data at AACR showed activity in ovarian, NSCLC, prostate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000095017025070291/0000950170-25-070291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000095017025070291/olma-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer